Evaluating Disparities in Precision Oncology

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT06081517
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Cancer
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Social Determinants of Health and toxicity questionnaires — BEHAVIORAL
    Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.

Study Details

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

Key Dates

Start date
Jan 26, 2024
Status verified
Jun 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
10,600 participants (estimated)

Arms

  • Arm: Black patients with advanced cancer
  • Arm: Non Black patients with advanced cancer

Primary Outcome Measure

Compare Overall Survival between Black patients and White patients (self-reported race) with advanced cancer [ Time Frame: through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Health Melvin and Bren Simon Comprehensive Cancer CenterIndianapolisIndiana46202
Maria McQuade, BA
[email protected]
(317) 278-5238
Bryan Schneider, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center· Indianapolis, IN

Related Studies